Clinical trials
Phase 1/2 Gastrointestinal Neoplasms trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
40 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2002 | 1 |
| 2003 | 1 |
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 1 |
| 2011 | 2 |
| 2015 | 1 |
| 2017 | 3 |
| 2018 | 2 |
| 2019 | 4 |
| 2020 | 3 |
| 2021 | 2 |
| 2022 | 3 |
| 2023 | 4 |
| 2024 | 3 |
| 2025 | 2 |
| 2026 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 14 |
| Completed | 11 |
| Terminated | 8 |
| Active, not recruiting | 4 |
| Withdrawn | 2 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Revolution Medicines, Inc. | 4 |
| National Cancer Institute (NCI) | 3 |
| DualityBio Inc. | 2 |
| Academic and Community Cancer Research United | 1 |
| Anup Kasi | 1 |
| BicycleTx Limited | 1 |
| BigHat Biosciences, Inc. | 1 |
| Bolt Biotherapeutics, Inc. | 1 |
| Columbia University | 1 |
| Dana-Farber Cancer Institute | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Gastrointestinal Neoplasms | 40 |
| Colorectal Neoplasms | 17 |
| Neoplasms | 14 |
| Pancreatic Neoplasms | 13 |
| Colonic Neoplasms | 12 |
| Stomach Neoplasms | 12 |
| Carcinoma, Non-Small-Cell Lung | 10 |
| Lung Neoplasms | 10 |
| Neoplasm Metastasis | 10 |
| Digestive System Neoplasms | 7 |
Trials
Showing 1 to 25 of 40. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.